Metformin Alters the Duodenal Microbiome and Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity

Posted by: | October 9, 2019 | Comments

ABSTRACT

Metformin Alters the Duodenal Microbiome and Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity

Background: Pancreatic ductal adenocarcinoma’s (PDAC) growing incidence has been linked to the rise in obesity and type 2 diabetes mellitus. In previous work we have shown that metformin can prevent the increased incidence of PDAC in a KrasG12D mouse model subjected to a diet high in fat and calories (HFCD). One potential way that metformin can affect the host is through alterations in the gut microbiome. Therefore, we investigated microbial associations with PDAC development and metformin use in the same mouse model. Methods: LSL-KrasG12D/+; p48-Cre (KC) mice were given control diet (CD), HFCD, or HFCD with 5 mg/ml metformin in drinking water for 3 months. 16S rRNA sequencing was performed at the end of the 3 months to characterize microbiome composition of duodenal mucosal, duodenal luminal, and cecal luminal samples.

Read more at: Physiology

Tien S Dong, Hui-Hua Chang, Meg Hauer, Venu Lagishetty, William Katzka, Enrique Rozengurt, Jonathan P. Jacobs, and Guido Eibl. American Journal of Physiology. DOI: https://doi.org/10.1152/ajpgi.00170.2019. 23 Sep 2019.





Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required
Privacy Policy




Terms & Conditions | Privacy Policy | © 2019 The Translational Microbiome Research Forum